The short answer
An effect of St John’s wort on fluphenazine absorption or treatment control has not been established. Have the extract and other medicines reviewed before starting or stopping it; interactions with other drugs do not prove this exact one.
What this answer covers
Oral fluphenazine with the exact supplement preparation described.
- Supplement or preparation
- Hypericum perforatum
- Medication ingredient
- fluphenazine
The herb affects selected medicine pathways
A human enzyme-probe study found increased CYP3A4 activity after a particular St John’s wort regimen, but no significant CYP1A2 or CYP2D6 effect from that herb. This is useful mechanistic evidence, not a study in patients taking fluphenazine.
The exact-moiety animal study was negative
A rat experiment used injected fluphenazine enanthate and oral Hypericum. The herb did not change the measured chewing movements or locomotion. This retains a contrary result, but neither motor behavior nor a depot rat regimen measures human oral hydrochloride absorption.
No validated hours-apart rule was found
The inspected sources do not show that separating these products preserves treatment or prevents adverse effects. Starting or stopping a pharmacologically active extract can have a different effect from moving one dose to another time.
Coordinate changes with the prescriber
Discuss the actual extract, dose and reason for use before changing either product. Do not increase or stop fluphenazine to compensate for a predicted interaction that has not been established for the combination.
Evidence and practical considerations
Absorption & effectiveness
An effect of St John’s wort on fluphenazine absorption or treatment control has not been established. Have the extract and other medicines reviewed before starting or stopping it; interactions with other drugs do not prove this exact one.
- Exact scope
- Oral fluphenazine with the exact supplement preparation described. with Oral fluphenazine with the stated label and formulation limits.
- Medication form and route
- oral
What remains uncertain
- Original exact-pair exposure, toxicity and timing propositions insufficient unless individually specified below. Human CYP3A4 probe induction does not establish the target medicine concentration or clinical response. No protective gap or automatic dose adjustment. Depot enanthate rat motor-null retained; not human oral hydrochloride PK.
Factors that may matter: Exact preparation and amount; Other medicines; Seizure history, alertness or electrolyte status where relevant.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral fluphenazine.
May cause drowsiness or lethargy. Hypotension is not usually a problem but can occur. Atropine and similar agents may potentiate anticholinergic activity. Caution with seizure history.
How this applies: Exact ingredient and oral-route clinical context.
Label class warnings do not establish every exact botanical interaction, event rate or protective supplement interval.
Source 2: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
St John’s wort has important interactions with certain medicines. Adult adverse effects include dizziness, restlessness and trouble sleeping.
How this applies: Selected medicine interactions and supplement adverse effects do not prove every antipsychotic exposure or sedation claim.
General guidance does not quantify this exact medication combination or establish a universal protective interval.
Source 3: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twelve older adults in a supplement and enzyme-probe study.
St John’s wort increased CYP3A4 probe activity, with no significant CYP1A2 or CYP2D6 effect identified for that herb.
How this applies: Mechanistic human context with exact substrate limits.
No target antipsychotic was administered. Results depend on extract and enzyme substrate; CYP3A4 induction does not establish CYP2D6-driven medicine loss of effect.
Source 4: Original animal study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Rats receiving a depot neuroleptic experimental regimen.
Hypericum did not change the fluphenazine-associated vacuous chewing movements or locomotion under the tested conditions.
How this applies: Exact active-moiety animal counterevidence with formulation and endpoint limits.
Rat motor model, not human oral fluphenazine hydrochloride pharmacokinetics or treatment control.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked draft with exact preparation limits, original study findings and uncertainty. Clinical review not recorded. | |
| Research summary published |
Article revision: 886ff88ed1cd3bd1
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.